<DOC>
	<DOCNO>NCT00129155</DOCNO>
	<brief_summary>In study , treosulfan evaluate condition allogenic stem cell transplantation . The procedure follow-up standard allogenic transplant . The donor unrelated ( identical HLA ) . The graft haematological peripheral blood stem cell . The conditioning reduced intensity : fludarabine ( day -6 day -2 ) , treosulfan ( day -6 day -4 ) thymoglobuline ( day -2 day -1 ) .</brief_summary>
	<brief_title>MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® Allogeneic Stem Cell Transplantation Patients With Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>AGE : &gt; = 18 year &lt; = 65 year Patients high transplantrelated mortality ( TRM ) standard transplantation ( multiple myeloma , chronic lymphoid leukemia , non Hodgkin 's lymphoma , myelodysplasia ) Patients visceral contraindication standard transplantation : cardiac : myocardiopathy ; force expiratory volume ( FEV ) &lt; 50 % ; respiratory : abnormal carbon monoxide diffuse capacity ( DLCO ) ; renal : creatinine clearance &lt; 50ml/min ; hepatic : transaminase bilirubin &gt; 2 upper normal limit ; infectious : control fungal infection . Karnofsky score &gt; = 70 % Unrelated donor HLA identical ( ABC , DRB1 ; DQB1 ) Signed informed consent Diagnosis : Chronic myelogenous leukemia ( CML ) : In first chronic phase , resistant interferon without aracytine refractory resistant Glivec In complete response ( CR ) 2nd partial response ( PR ) blastic phase Multiple myeloma ( MM ) : Relapse autograft therapeutic response evaluate 50 % NonHodgkin 's lymphoma ( NHL ) : Mantle cell lymphoma first relapse case chemosensitivity ≥ 50 % except high grade lymphoma In 2nd CR PR chemosensitive response ≥ 50 % autograft Chronic lymphocytic leukemia ( CLL ) : In 2nd CR PR response ≥ 50 % autograft 2nd relapse 2 line treatment case chemosensitivity ≥ 50 % Acute myeloid leukemia ( AML ) : In 2nd CR 1st CR high risk criterion [ high risk criterion define : LAM 7 ; leukocyte &gt; 30,000/mm3 ; chromosomal abnormality : ( 6,9 ) ; abnormalities 11q23 , 17p , 11q , 20q , 21q , 5 , del ( 5q ) , 7/del7q , del 9q et inv 3q ] Acute lymphoblastic leukemia ( ALL ) : In 2nd CR 1st CR high risk criterion patient define chromosomal abnormality ( 9,22 ) ; ( 1,19 ) ; ( 4,11 ) ; abnormalities 11q23 Myelodysplastic syndrome ( MDS ) : Patients without prior chemotherapy , intermediate high International Prognostic Scoring System ( IPSS ) score blast cell &lt; 1 % bone marrow ( BM ) CR PR chemotherapy patient 20 30 % blast cell BM Secondary AML patient response chemotherapy ( &lt; 30 % blast BM &lt; 5 % blast cell blood ) For : Adequate contraception female patient child bear potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Allogenic stem cell transplantation</keyword>
	<keyword>Treosulfan</keyword>
	<keyword>Haematological malignancy</keyword>
	<keyword>allogeneic stem cell transplantation patient hematological malignancy</keyword>
</DOC>